Supplementation with the extract of schisandrae fructus pulp, seed, or their combination influences the metabolism of lipids and glucose in mice fed with normal and hypercholesterolemic diet

Evidence-based Complementary and Alternative Medicine

Volumn 2014, Issue , 2014, Pages

  Wang, Xiao Yan ^a   Yu, Zhi Ling ^b   Pan, Si Yuan ^a   Zhang, Yi ^a   Sun, Nan ^a   Zhu, Pei Li ^a   Jia, Zhan Hong ^a   Zhou, Shu Feng ^c   Ko, Kam Ming ^d  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CHOLESTEROL; GLUCOSE; LIPID; PLANT EXTRACT; SCHISANDRAE FRUCTUS EXTRACT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; DIET SUPPLEMENTATION; FRUIT; GLUCOSE LIVER LEVEL; GLUCOSE METABOLISM; HYPERCHOLESTEROLEMIA; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPID LIVER LEVEL; LIPID METABOLISM; LIVER FUNCTION; LIVER INJURY; LIVER LEVEL; LIVER WEIGHT; MALE; MOUSE; NONHUMAN; PLANT SEED; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84901279947     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2014/472638     Document Type: Article

References (57)

1. Nelson R. H., Hyperlipidemia as a risk factor for cardiovascular disease. Primary Care 2013 40 1 195 211
2. van Craeyveld E., Gordts S. C., Jacobs F., de Geest B., Correlation of atherosclerosis between different topographic sites is highly dependent on the type of hyperlipidemia. Heart and Vessels 2012 27 2 231 234 2-s2.0-78751647903 10.1007/s00380-010-0098-9
3. Loria P., Marchesini G., Nascimbeni F., Ballestri S., Maurantonio M., Carubbi F., Ratziu V., Lonardo A., Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. Atherosclerosis 2014 232 1 99 109
4. Ip B. C., Wang X. D., Non-alcoholic steatohepatitis and hepatocellular carcinoma: implications for lycopene intervention. Nutrients 2013 6 1 124 162
5. Lin X. F., Shi K. Q., You J., Liu W. Y., Luo Y. W., Wu F. L., Chen Y. P., Wong D. K., Yuen M. F., Zheng M. H., Increased risk of colorectal malignant neoplasm in patients with nonalcoholic fatty liver disease: a large study. Molecular Biology Reports 2014 10.1007/s11033-014-3157-y
6. Sung K. C., Wild S. H., Byrne C. D., Development of new fatty liver, or resolution of existing fatty liver, over five years of follow up, and risk of incident hypertension. Journal of Hepatology 2014 10.1016/j.jhep.2014.01.009
7. Masuoka H. C., Chalasani N., Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Annals of the New York Academy of Sciences 2013 1281 106 122
8. Tian C. R., Qian L., Du C. L., Shen X. Z., Increased catabolism of nucleic acid in nonalcoholic fatty liver disease patients of different ages. International Journal of Biological Macromolecules 2014 65 107 109
9. Eguchi A., Povero D., Alkhouri N., Feldstein A. E., Novel therapeutic targets for nonalcoholic fatty liver disease. Expert Opinion on Therapeutic Targets 2013 17 7 773 779
10. di Stasi S. L., MacLeod T. D., Winters J. D., Binder-Macleod S. A., Effects of statins on skeletal muscle: a perspective for physical therapists. Physical Therapy 2010 90 10 1530 1542 2-s2.0-79952857002 10.2522/ptj.20090251
11. Pettersen J. C., Pruimboom-Brees I., Francone O. L., Amacher D. E., Boldt S. E., Kerlin R. L., Ballinger W. E., The PPAR α agonists fenofibrate and CP-778875 cause increased β -oxidation, leading to oxidative injury in skeletal and cardiac muscle in the rat. Toxicologic Pathology 2012 40 3 435 447
12. Buyukhatipoglu H., Sezen Y., Guntekin U., Kirhan I., Dag O. F., Acute renal failure with the combined use of rosuvastatin and fenofibrate. Renal Failure 2010 32 5 633 635 2-s2.0-77952971115 10.3109/08860221003759452
13. Alla V. M., Agrawal V., DeNazareth A., Mohiuddin S., Ravilla S., Rendell M., A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs. Drugs 2013 73 10 1025 1054
14. Carreau V., Girardet J.-P., Bruckert E., Long-term follow-up of statin treatment in a cohort of children with familial hypercholesterolemia: efficacy and tolerability. Pediatric Drugs 2011 13 4 267 275 2-s2.0-79959606300 10.2165/11591650-000000000-00000
15. Liu Z. L., Li G. Q., Bensoussan A., Kiat H., Chan K., Liu J. P., Chinese herbal medicines for hypertriglyceridaemia. The Cochrane Database of Systematic Reviews 2013 6 CD009560
16. Wider B., Pittler M. H., Thompson-Coon J., Ernst E., Artichoke leaf extract for treating hypercholesterolaemia. The Cochrane Database of Systematic Reviews 2013 4 CD003335 2-s2.0-75349114461
17. Takimoto Y., Qian H. Y., Yoshigai E., Okumura T., Ikeya Y., Nishizawa M., Gomisin N in the herbal drug gomishi (Schisandra chinensis) suppresses inducible nitric oxide synthase gene via C/EBP β and NF- B in rat hepatocytes. Nitric Oxide 2013 28 47 56
18. Xu Y., Liu Z., Sun J., Pan Q., Sun F., Yan Z., Hu X., Schisandrin B prevents doxorubicin-induced chronic cardiotoxicity and enhances its anticancer activity in vivo. PLoS ONE 2011 6 12 2-s2.0-82555187159 10.1371/journal.pone. 0028335 e28335
19. Bi H., Li F., Krausz K. W., Qu A., Johnson C. H., Gonzalez F. J., Targeted metabolomics of serum acylcarnitines evaluates hepatoprotective effect of wuzhi tablet (schisandra sphenanthera extract) against acute acetaminophen toxicity. Evidence-Based Complementary and Alternative Medicine 2013 2013 13 985257 10.1155/2013/985257
20. Panossian A., Wikman G., Pharmacology of Schisandra chinensis Bail.: an overview of Russian research and uses in medicine. Journal of Ethnopharmacology 2008 118 2 183 212 2-s2.0-45449105337 10.1016/j.jep.2008.04.020
21. Park H. J., Lee S. J., Song Y., Jang S. H., Ko Y. G., Kang S. N., Chung B. Y., Kim H. D., Kim G. S., Cho J. H., Schisandra chinensis prevents alcohol-induced fatty liver disease in rats. Journal of Medicinal Food 2014 17 1 103 110
22. Tatewaki N., Nishida H., Yoshida M., Ando H., Kondo S., Sakamaki T., Konishi T., Differential effect of schisandrin B stereoisomers on ATR-mediated DNA damage checkpoint signaling. Journal of Pharmacological Sciences 2013 122 2 138 148
23. Pan S.-Y., Yu Z.-L., Dong H., Xiang C.-J., Fong W.-F., Ko K.-M., Ethanol extract of fructus schisandrae decreases hepatic triglyceride level in mice fed with a high fat/cholesterol diet, with attention to acute toxicity. Evidence-based Complementary and Alternative Medicine 2011 2011 6 2-s2.0-79952145519 10.1093/ecam/nep070 729412
24. Pan S. Y., Yu Q., Zhang Y., Wang X. Y., Sun N., Yu Z. L., Ko K. M., Dietary Fructus Schisandrae extracts and fenofibrate regulate the serum/hepatic lipid-profile in normal and hypercholesterolemic mice, with attention to hepatotoxicity. Lipids in Health and Disease 2012 11 120 10.1186/1476-511X-11- 120
25. Pan S.-Y., Dong H., Zhao X.-Y., Xiang C.-J., Fang H.-Y., Fong W.-F., Yu Z.-L., Ko K.-M., Schisandrin B from Schisandra chinensis reduces hepatic lipid contents in hypercholesterolaemic mice. The Journal of Pharmacy and Pharmacology 2008 60 3 399 403 2-s2.0-39449088904 10.1211/jpp.60.3.0017 (Pubitemid 351269829)
26. Pan S.-Y., Dong H., Yu Z.-L., Zhao X.-Y., Xiang C.-J., Wang H., Fong W.-F., Ko K.-M., Bicyclol, a synthetic dibenzocyclooctadiene derivative, decreases hepatic lipids but increases serum triglyceride level in normal and hypercholesterolaemic mice. The Journal of Pharmacy and Pharmacology 2007 59 12 1657 1662 2-s2.0-36849043037 10.1211/jpp.59.12.0007 (Pubitemid 350221810)
27. Pan S.-Y., Yang R., Dong H., Yu Z.-L., Ko K.-M., Bifendate treatment attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in mice. European Journal of Pharmacology 2006 552 1-3 170 175 2-s2.0-33750471637 10.1016/j.ejphar.2006.09.011 (Pubitemid 44648081)
28. Yang X. R., Wat E., Wang Y. P., Ko C. H., Koon C. M., Siu W. S., Gao S., Cheung D. W., Lau C. B., Ye C. X., Leung P. C., Effect of dietary cocoa tea (Camellia ptilophylla) supplementation on high-fat diet-induced obesity, hepatic steatosis, and hyperlipidemia in mice. Evidence-Based Complementary and Alternative Medicine 2013 2013 11 783860 10.1155/2013/783860
29. Gu M., Fan S., Liu G., Guo L., Ding X., Lu Y., Zhang Y., Ji G., Huang C., Extract of wax gourd peel prevents high-fat diet-induced hyperlipidemia in C57BL/6 mice via the inhibition of the PPAR γ pathway. Evidence-Based Complementary and Alternative Medicine 2013 2013 11 342561 10.1155/2013/342561
30. Zelber-Sagi S., Salomone F., Yeshua H., Lotan R., Webb M., Halpern Z., Santo E., Oren R., Shibolet O., Non-high-density lipoprotein cholesterol independently predicts new onset of non-alcoholic fatty liver disease. Liver International 2013 10.1111/liv.12318
31. Fernandez M. L., Webb D., The LDL to HDL cholesterol ratio as a valuable tool to evaluate coronary heart disease risk. Journal of the American College of Nutrition 2008 27 1 1 5 2-s2.0-42649113092 (Pubitemid 351600516)
32. Liang H., Chen X., Chen Q., Wang Y., Wu X., Li Y., Pan B., Liu H., Li M., The metabolic syndrome among postmenopausal women in rural Canton: prevalence, associated factors, and the optimal obesity and atherogenic indices. PLoS ONE 2013 8 9 e74121
33. Landén M., Baghaei F., Rosmond R., Holm G., Björntorp P., Eriksson E., Dyslipidemia and high waist-hip ratio in women with self-reported social anxiety. Psychoneuroendocrinology 2004 29 8 1037 1046 2-s2.0-3042547389 10.1016/j.psyneuen.2003.10.006 (Pubitemid 38833531)
34. Baligadoo S., Elevated coronary mortality in Mauritius: risk factors and genetic analyses. Bulletin de L'Académie NationaLe de Médecine 2012 196 7 1381 1394
35. Masana L., Ibarretxe D., Heras M., Cabré A., Ferré R., Merino J., Plana N., Girona J., Substituting non-HDL cholesterol with LDL as a guide for lipid-lowering therapy increases the number of patients with indication for therapy. Atherosclerosis 2013 226 2 471 475
36. Tsi D., Tan A., Evaluation on the combined effect of Sesamin and Schisandra extract on blood fluidity. Bioinformation 2008 2 6 249 252
37. Iori E., Vinci B., Murphy E., Marescotti M. C., Avogaro A., Ahluwalia A., Glucose and fatty acid metabolism in a 3 tissue in-vitro model challenged with normo- and hyperglycaemia. PLoS ONE 2012 7 4 2-s2.0-84859560833 10.1371/journal.pone.0034704 e34704
38. Elshourbagy N. A., Meyers H. V., Abdel-Meguid S. S., Cholesterol: the good, the bad, and the ugly-therapeutic targets for the treatment of dyslipidemia. Medical Principles and Practice 2014 23 2 99 111
39. Chu J.-H., Wang H., Ye Y., Chan P.-K., Pan S.-Y., Fong W.-F., Yu Z.-L., Inhibitory effect of schisandrin B on free fatty acid-induced steatosis in L-02 cells. World Journal of Gastroenterology 2011 17 19 2379 2388 2-s2.0-79957845984 10.3748/wjg.v17.i19.2379
40. Okumura T., Role of lipid droplet proteins in liver steatosis. Journal of Physiology and Biochemistry 2011 67 4 629 636 2-s2.0-84857394687
41. Müller-Wieland D., Knebel B., Haas J., Kotzka J., SREBP-1 and fatty liver-clinical relevance for diabetes, obesity, dyslipidemia and atherosclerosis. Herz 2012 37 3 273 278 2-s2.0-84858727045 10.1007/s00059-012- 3608-y
42. Kwon D. Y., Kim D. S., Yang H. J., Park S., The lignan-rich fractions of Fructus Schisandrae improve insulin sensitivity via the PPAR- γ pathways in in vitro and in vivo studies. Journal of Ethnopharmacology 2011 135 2 455 462 2-s2.0-79955682914 10.1016/j.jep.2011.03.037
43. Joseph B., Kapoor S., Schilsky M. L., Gupta S., Bile salt-induced pro-oxidant liver damage promotes transplanted cell proliferation for correcting Wilson disease in the Long-Evans Cinnamon rat model. Hepatology 2009 49 5 1616 1624 2-s2.0-66149110340 10.1002/hep.22792
44. Allen K., Jaeschke H., Copple B. L., Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis. American Journal of Pathology 2011 178 1 175 186 2-s2.0-78650793157 10.1016/j.ajpath.2010.11.026
45. Yan F., Zhang Q.-Y., Jiao L., Han T., Zhang H., Qin L.-P., Khalid R., Synergistic hepatoprotective effect of Schisandrae lignans with Astragalus polysaccharides on chronic liver injury in rats. Phytomedicine 2009 16 9 805 813 2-s2.0-67650542086 10.1016/j.phymed.2009.02.004
46. Sahebkar A., Chew G. T., Watts G. F., New peroxisome proliferator- activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liverdisease. Expert Opinion on Pharmacotherapy 2014 15 4 493 503
47. Kostapanos M. S., Kei A., Elisaf M. S., Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease. World Journal of Hepatology 2013 5 9 470 478
48. Ferreira A. V., Menezes-Garcia Z., Mario E. G., Delpuerto H. L., Martins A. S., Botion L. M., Increased expression of oxidative enzymes in adipose tissue following PPARa-activation. Metabolism 2014 63 4 456 460
49. Gandhi N., Lenton R., Bhartia M., Abbas A., Raju J., Ramachandran S., Effect of fibrate treatment on liver function tests in patients with the metabolic syndrome. Springerplus 2014 3 14 10.1186/2193-1801-3-14
50. Mohamed D. I., Elmelegy A. A., El-Aziz L. F., Abdel Kawy H. S., El-Samad A. A., El-Kharashi O. A., Fenofibrate A peroxisome proliferator activated receptor- α agonist treatment ameliorates Concanavalin A-induced hepatitis in rats. European Journal of Pharmacology 2013 721 1-3 35 42
51. Hajdu D., Aiglová K., Vinklerová I., Urbánek K., Acute cholestatic hepatitis induced by fenofibrate. Journal of Clinical Pharmacy and Therapeutics 2009 34 5 599 602
52. Tudesq N., Bentounes M., Hepatitis induced by fibrates. Annales de Biologie Clinique 2006 64 5 515 516 2-s2.0-33750367315 10.1684/abc.2006.0020 (Pubitemid 44627919)
53. Maroy B., Acute cholestatic hepatitis probably due to fenofibrate. Therapie 2010 65 2 147 148 2-s2.0-77952780799 10.2515/therapie/2010011
54. Kobayashi A., Suzuki Y., Kuno H., Sugai S., Sakakibara H., Shimoi K., Effects of fenofibrate on plasma and hepatic transaminase activities and hepatic transaminase gene expression in rats. Journal of Toxicological Sciences 2009 34 4 377 387 2-s2.0-68549106059 10.2131/jts.34.377
55. Li L. S., Shi W. J., Ma X. B., Comparative analysis of bioactive component in seeds and flesh of Schisandrae chinensis Fructus by thin layer chromatography. Food Science 2012 33 16 175 178
56. Li L., Xiao Y., Yu D., Ma Y., Huang W., Tian G., Chen L., Determination of three organic acids in Schisandrae Chinensis Fructus by HPLC. China Journal of Chinese Materia Medica 2011 36 23 3286 3289 2-s2.0-84857275463 10.4268/cjcmm20112314
57. Schwarzinger C., Kranawetter H., Analysis of the active compounds in different parts of the Schisandra chinensis plant by means of pyrolysis-GC/MS. Monatshefte fur Chemie 2004 135 9 1201 1208 2-s2.0-4644231654 10.1007/s00706-004-0176-8 (Pubitemid 39286501)